CALM IVF (Creating Affiliations, Learning, and Mindfulness for In Vitro Fertilization Patients)

September 30, 2026 updated by: University of Iowa

Creating Affiliations, Learning, and Mindfulness for In Vitro Fertilization Patients

The investigators have designed a psychoeducational group curriculum specifically for new in vitro fertilization (IVF) patients (both male and female) to improve their treatment knowledge, to allow them to engage more in their care, to offer a support network, to improve satisfaction, and to provide them with tools to help reduce their stress and anxiety while undergoing the IVF process. The investigators plan to have four to eight infertility patients and their partners participate in a group at a time, for which they will attend three 1-1.5 hour interactive sessions that are scheduled throughout their first IVF cycle. These sessions will provide additional time for discussion about treatment with providers, learning opportunities on topics of interest to fertility patients, and stress reduction techniques. They will do several surveys before and after the intervention for comparison, including assessment of quality of life, depression, anxiety, resilience, and a knowledge assessment. The investigators will also track the patients to see if they pursue additional treatment in the instance of a negative pregnancy test compared to patients undergoing the standard treatment. The investigators plan to recruit a control group that receives the standard of care treatment here at the University of Iowa.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Patients and their partners (if present and consenting) will be randomized in a 2:1 fashion to two different treatment arms: A) standard of care in vitro fertilization (IVF) at the investigational institution as well as participating in an additional psychoeducational group or B) standard of care IVF at the investigational institution. The intervention group will consist of three additional evening visits for 1-1.5 hours per session. The sessions will include an interactive educational component addressing usual questions and concerns of IVF patients, such as reviewing common IVF myths, and also more information regarding treatment and technologies. Each session will also include teaching of coping strategies (such as awaiting the pregnancy test, how to cope with insensitive remarks from friends and family) as well as relaxation exercises, such as progressive muscle relaxation and deep breathing.

The patients will be consented at their new IVF visit and will take their initial assessments (FertiQoL, GAD-7, PHQ-9, the Connor-Davidson Resilience Scale, and a knowledge assessment) within 24 hours of the new visit. The patients will be assigned into groups based on when they are going through their IVF stimulations, so they will have similar experiences at similar times. Patients will take their final assessments on the third day after egg retrieval, regardless of group assignment.

When partners are present and consent to the study, they will be treated as a dyad with the patient undergoing oocyte retrieval. Some patients go through treatment alone (i.e. single adults desiring pregnancy) and therefore may not have a partner available to participate. Partners level of involvement in a cycle may very, as may their desire to participate in a psychosocial intervention. As patients and their partners make joint decisions throughout their IVF cycle and the cycle itself has a single outcome, we enrolled partners as dyads with patients when partners were present, but did not require a partner to enroll a patient.

Study Type

Interventional

Enrollment (Actual)

117

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Iowa
      • Iowa City, Iowa, United States, 52242
        • University of Iowa Hospitals and Clinics

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 99 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • All patients starting their first in vitro fertilization cycle at the University of Iowa Hospitals and Clinics

Exclusion Criteria:

  • Patients who have already undergone in vitro fertilization treatment at any institution
  • Non-English speakers
  • Fertility preservation patients
  • Patients using donor oocytes, embryos, or sperm
  • Patients taking psychotropic medications for depression or anxiety that have had a dosing adjustment within 3 months of study enrollment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention

Standard of care in vitro fertilization patients randomized to the psychoeducational group intervention.

The intervention will be three 1-1.5 hour interactive sessions that are scheduled throughout the participant's first in vitro fertilization cycle. These sessions will provide additional time for discussion about treatment with providers, learning opportunities on topics of interest to fertility patients, and stress reduction techniques.

Other: Control

Standard of care in vitro fertilization patients at our institution.

Patients will receive the standard of care IVF treatment at the University of Iowa.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in female fertility patient quality of life score during IVF treatment cycle
Time Frame: From enrollment to 2-4 days after oocyte retrieval

FertiQoL International (Fertility Quality of Life Questionnaire 2008), scored scale from 0-100, with higher values indicating a higher quality of life and low scores indicating a lower quality of life.

From enrollment to 2-4 days after oocyte retrieval

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in female GAD-7 score during IVF treatment cycle
Time Frame: From enrollment to 2-4 days after oocyte retrieval

Generalized Anxiety Disorder 7-item scale, with higher scores indicating higher likelihood of an anxiety disorder and lower scores indicating less likelihood of an anxiety disorder.

From enrollment to 2-4 days after oocyte retrieval
Change in female PHQ-9 score during IVF treatment cycle
Time Frame: From enrollment to 2-4 days after oocyte retrieval

Patient Health Questionnaire, with higher score indicating increased likelihood of a depressive disorder and lower scores indicating less likelihood of a depressive disorder.

From enrollment to 2-4 days after oocyte retrieval
Change in female Connor-Davidson Resilience Scale during IVF treatment cycle
Time Frame: From enrollment to 2-4 days after oocyte retrieval

Connor-Davidson Resilience Scale, with higher scores indicating greater resilience, and lower scores indicating lower resilience

From enrollment to 2-4 days after oocyte retrieval
Change in female knowledge assessment during IVF treatment cycle
Time Frame: From enrollment to 2-4 days after oocyte retrieval

Assessment of knowledge regarding IVF treatment, with higher scores indicating a greater knowledge of IVF treatment, and lower scores indicating less knowledge regarding IVF treatment

From enrollment to 2-4 days after oocyte retrieval
Likelihood of continued IVF treatment in the instance of a negative pregnancy test
Time Frame: Three months after embryo transfer

Patients who are not pregnant after embryo transfer will be followed for three months to assess likelihood to return for additional treatment after negative embryo transfer outcome.

Three months after embryo transfer
Change in male fertility patient quality of life score during IVF treatment cycle
Time Frame: From enrollment to 2-4 days after oocyte retrieval

FertiQoL International (Fertility Quality of Life Questionnaire 2008), scored scale from 0-100, with higher values indicating a higher quality of life and low scores indicating a lower quality of life.

From enrollment to 2-4 days after oocyte retrieval
Change in male GAD-7 score during IVF treatment cycle
Time Frame: From enrollment to 2-4 days after oocyte retrieval

Generalized Anxiety Disorder 7-item scale, with higher scores indicating higher likelihood of an anxiety disorder and lower scores indicating less likelihood of an anxiety disorder.

From enrollment to 2-4 days after oocyte retrieval
Change in male PHQ-9 score during IVF treatment cycle
Time Frame: From enrollment to 2-4 days after oocyte retrieval

Patient Health Questionnaire, with higher score indicating increased likelihood of a depressive disorder and lower scores indicating less likelihood of a depressive disorder.

From enrollment to 2-4 days after oocyte retrieval
Change in male Connor-Davidson Resilience Scale during IVF treatment cycle
Time Frame: From enrollment to 2-4 days after oocyte retrieval

Connor-Davidson Resilience Scale, with higher scores indicating greater resilience, and lower scores indicating lower resilience

From enrollment to 2-4 days after oocyte retrieval
Change in male knowledge assessment during IVF treatment cycle
Time Frame: From enrollment to 2-4 days after oocyte retrieval

Assessment of knowledge regarding IVF treatment, with higher scores indicating a greater knowledge of IVF treatment, and lower scores indicating less knowledge regarding IVF treatment

From enrollment to 2-4 days after oocyte retrieval

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Rachel M Whynott, MD, University of Iowa

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 9, 2019

Primary Completion (Actual)

August 9, 2021

Study Completion (Actual)

October 26, 2021

Study Registration Dates

First Submitted

August 5, 2019

First Submitted That Met QC Criteria

August 5, 2019

First Posted (Actual)

August 7, 2019

Study Record Updates

Last Update Posted (Actual)

October 2, 2026

Last Update Submitted That Met QC Criteria

September 30, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 201906788

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.